Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ARYD Stock Forecast 2026-2027
$0.76
Current Price
$6.03M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ARYD Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
ARYD Price Momentum
+1.3%
1 Week Change
-11.6%
1 Month Change
-32.7%
1 Year Change
-26.9%
Year-to-Date Change
-70.5%
From 52W High of $2.58
+8.7%
From 52W Low of $0.70
📊 TOP ANALYST CALLS
Did ARYD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ARYD is one of their latest high-conviction picks.
Latest ARYD Stock Price Targets & Analyst Predictions
ARYD has shown a year-to-date change of -26.9% and a 1-year change of -32.7%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for ARYD. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ARYD Analyst Ratings
0
Buy
0
Hold
0
Sell
ARYD Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.76
Latest ARYD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ARYD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
ARYA Sciences Acquisition Corp IV (ARYD) Competitors
The following stocks are similar to ARYD based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ARYA Sciences Acquisition Corp IV (ARYD) Financial Data
Valuation Metrics
Market Cap
$6.03M
Enterprise Value
$0
P/E Ratio
188.2x
PEG Ratio
-0.5x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+1.5%
Current Ratio
0.0x
Debt/Equity
0.0x
ROE
-8.3%
ROA
-5.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
ARYA Sciences Acquisition Corp IV (ARYD) Business Model
About ARYA Sciences Acquisition Corp IV
What They Do
Focuses on acquiring life sciences companies.
Business Model
The company operates as a blank check company, intending to merge with or acquire businesses primarily in the life sciences and medical technology sectors in North America and Europe. Its revenue generation will depend on successful business combinations that enhance value and growth.
Additional Information
Founded in 2020 and based in New York, Arya Sciences Acquisition Corp IV is positioned to capitalize on opportunities in the rapidly evolving life sciences industry, offering a potential investment avenue for those interested in innovative medical solutions.
Company Information
Sector
Financial Services
Industry
Shell Companies
Employees
0
CEO
Mr. Adam Leo Stone
Country
United States
IPO Year
2021
Website
www.perceptivelife.com/arya4ARYA Sciences Acquisition Corp IV (ARYD) Latest News & Analysis
Latest News
Quick Summary
Adagio Medical completed its business combination with ARYA Sciences Acquisition Corp IV, a SPAC, enhancing its position in catheter ablation technologies for cardiac arrhythmias.
Why It Matters
Adagio Medical's merger with ARYA IV enhances its market position and access to capital, potentially driving growth and innovation in cardiac treatment, influencing investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The Combined Company anticipates receiving around $42 million from equity and convertible note investors at closing.
Why It Matters
The $42 million funding indicates strong investor confidence, providing the combined company with capital for growth, potentially boosting its market position and stock value.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
ARYA Sciences Acquisition Corp IV (NASDAQ: ARYD) and Amicus Therapeutics (NASDAQ: FOLD) have mutually terminated their Business Combination Agreement due to current market conditions.
Why It Matters
The termination of the business combination between ARYA IV and Amicus may signal instability or unfavorable market conditions, potentially impacting stock prices and investor confidence in both companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ARYD Stock
What is ARYA Sciences Acquisition Corp IV's (ARYD) stock forecast for 2026?
Analyst forecasts for ARYA Sciences Acquisition Corp IV (ARYD) are not currently available. The stock is trading at $0.76.
Is ARYD stock a good investment in 2026?
Analyst ratings for ARYD are not currently available. The stock is currently trading at $0.76. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ARYD stock?
Price predictions from Wall Street analysts for ARYD are not currently available. The stock is trading at $0.76.
What is ARYA Sciences Acquisition Corp IV's business model?
The company operates as a blank check company, intending to merge with or acquire businesses primarily in the life sciences and medical technology sectors in North America and Europe. Its revenue generation will depend on successful business combinations that enhance value and growth.
What is the highest forecasted price for ARYD ARYA Sciences Acquisition Corp IV?
Price targets from Wall Street analysts for ARYD are not currently available. The stock is trading at $0.76.
What is the lowest forecasted price for ARYD ARYA Sciences Acquisition Corp IV?
Price targets from Wall Street analysts for ARYD are not currently available. The stock is trading at $0.76.
What is the overall ARYD consensus from analysts for ARYA Sciences Acquisition Corp IV?
Analyst ratings for ARYD are not currently available. The stock is trading at $0.76.
How accurate are ARYD stock price projections?
Stock price projections, including those for ARYA Sciences Acquisition Corp IV, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 10:39 AM UTC